Skip to main content

Table 2.

Results of treatment

Response
CR (including CRu)    11 (37%)
PR      7 (23%)
Relapsed disease status
 CR 10/25 (40%)
 PR  6/25 (34%)
Primary refractory
 CR   1/5 (20%)
 PR   1/5 (20%)
Survival (median follow‐up 32 months)
 Overall survival (4‐years) 28.2%
 Progression‐free survival (4‐years) 17.5%

CR, complete response; CRu, complete response uncertain; PR, partial remission.